Medical Center Leeuwarden   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Leeuwarden Netherlands (1982)

Organization Overview

First Clinical Trial
2004
NCT00138736
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Dept of intensive care, Medical Centre Leeuwarden, PO Box 888,8901BR Leeuwarden, The Netherlands | Medical Center Leeuwarden | Medical Centre Leeuwarden | Medical centrum Leeuwarden, Department of pulmonology | Medisch Centrum Leeuwarden

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Coronary Syndrome (Phase 4)

Angina, Unstable (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Squamous Cell (Phase 2)

Critical Illness (Phase 4)

Diabetes, Gestational (Phase 3)

Infarction (Phase 4)

Insulin Resistance (Phase 3)

Myocardial Infarction (Phase 4)

Neutropenia (Phase 2)

Non-ST Elevated Myocardial Infarction (Phase 4)

Pheochromocytoma (Phase 4)

Renal Insufficiency (Phase 3)

Sepsis (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 2)

Syndrome (Phase 4)

Ventricular Dysfunction (Phase 4)

Ventricular Dysfunction, Right (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 17
  • # of Trial APIs: 24